Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Soliris Market In 2029?

In recent times, the Soliris market has experienced substantial growth. The market size, which is projected to experience growth from $1,880.37 million in 2024, is expected to reach $2,030.44 million by 2025, with a compound annual growth rate (CAGR) of 8.0%. The surge seen in the historical timeline can be traced back to factors such as regulatory permissions, an increase in awareness of rare diseases, a rise in demand for complement inhibition, widened indications, and a boost in the rates of diagnosis.

What Growth Rate Is Forecasted for the Soliris Market by 2029?

The market size of Soliris is anticipated to experience robust growth in the coming years, increasing to $3,734.88 million in 2029 with a Compound Annual Growth Rate (CAGR) of 7.7%. This expansion in the predicted period can be credited to the escalating prevalence of diseases mediated by complement, advancements in gene therapy, growth of market access in newly developing regions, the spread of biosimilars, and enhanced adherence by patients. Dominant trends during the forecast period consist of the endorsement of combination therapies, an upward trend in treatments centered towards patients, a shift towards personalized medical care, an increase in the application of digital health technologies, along with an emphasis on cost-effectiveness and value-based treatment.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

Which Key Companies Are Shaping the Future of the Soliris Market?

Major companies operating in the soliris market include Pfizer

Which Factors Are Driving Demand in the Soliris Industry?

A surge in the incidence of rare blood diseases is anticipated to boost the soliris market’s expansion. Uncommon conditions that affect the production, constituents or coagulation of blood, like hemophilia, sickle cell anemia, and thalassemia, denote rare blood disorders. An increase in the occurrence of these disorders is typically attributed to enhanced diagnostic techniques, heightened awareness, and certain genetic and environmental factors. Soliris works by counteracting the complement protein C5, hence aiding patients with rare blood diseases by preventing an overactivity of complement, which in turn lowers the risk of serious complications like hemolysis and organ damage. This improves overall disease management, resulting in better outcomes for patients. For instance, the National Health Service (NHS) England asserted in May 2024 that nearly 17,000 people in England, living with inherited blood disorder known as sickle cell disease, with roughly 250 new cases being diagnosed every year have in turn contributed to the soliris market boom. The soliris market expansion is also influenced by the escalating investment in the research of rare diseases. The heightened investment in this research is driven by the burgeoning recognition of unmet healthcare necessities, advancements in genomics and prospective breakthrough therapies that can enhance patient outcomes. Increased funding for research on rare diseases encourages the growth of Soliris by enhancing the comprehension of underrepresented disorders, which leads to a rise in the demand for successful treatments. For example, the Department of Health and Science Care in the UK dedicated considerable funding in July 2023, inclusive of USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource. This initiative links genetic data to clinical traits over 50 rare diseases, consequently boosting diagnostic and therapeutic development. Consequently, the escalating investment in research pertaining to rare diseases is stimulating the soliris market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19933&type=smp

How Is the Soliris Market Segmented by Several Divisions?

The solirismarket covered in this report is segmented –

1) By Type: Plasma Exchange; Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH); Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

What are the Emerging Market Trends Driving the Growth of the Soliris Industry?

A primary trend emerging in the Soliris market is the increased concentration on the creation of biological medicines intended for neuromyelitis optica spectrum disorder (NMOSD) to improve treatment avenues for uncommon blood disorders. This is indicative of a substantial progression in managing NMOSD, a rare autoimmune condition affecting the central nervous system, by providing an efficacious solution to curb recurrent episodes and safeguard against further neurological impairment. For instance, in October 2023, Soliris (eculizumab) was granted approval by the National Medical Products Administration (NMPA) in China for the treatment of adults with NMOSD who tested positive for antibodies against aquaporin-4 (AQP4). AstraZeneca PLC, a pharmaceutical firm based in the UK, was responsible for this breakthrough. This approval signifies the first-ever endorsement of a complement inhibitor for NMOSD treatment in China.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Which Regions Are Driving Growth in the Soliris Market?

North America was the largest region in the Soliris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19933

This Report Delivers Insight On:

1. How big is the soliris market, and how is it changing globally?

2. Who are the major companies in the soliris market, and how are they performing?

3. What are the key opportunities and risks in the soliris market right now?

4. Which products or customer segments are growing the most in the soliris market?

5. What factors are helping or slowing down the growth of the soliris market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model